Trypanosoma cruzi exposes phosphatidylserine as an evasion mechanism.

FEMS Microbiol Lett

Laboratório de Biologia Celular e Tecidual, Universidade Federal do Rio de Janeiro, Rio de Janerio, RJ, Brazil.

Published: January 2007

Chagas disease is caused by Trypanosoma cruzi and affects 18 million people in Central and South America. Here we analyzed the exposure of phosphatidylserine by the different forms of the parasite life cycle. Only the infective trypomastigotes, but not the epimastigotes or intracellular amastigotes, expose this phospholipid. This triggers a transforming growth factor beta signaling pathway, based on phosphorylated Smad 2 nuclear translocation, leading to iNOS disappearance in infected macrophages. This macrophage deactivation favors the survival of this intracellular parasite. Thus, phosphatidylserine exposure may be used by T. cruzi to evade innate immunity and be a common feature of obligate intracellular parasites that have to deal with activated macrophages.

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1574-6968.2006.00495.xDOI Listing

Publication Analysis

Top Keywords

trypanosoma cruzi
8
cruzi exposes
4
exposes phosphatidylserine
4
phosphatidylserine evasion
4
evasion mechanism
4
mechanism chagas
4
chagas disease
4
disease caused
4
caused trypanosoma
4
cruzi people
4

Similar Publications

Discovery of a Potent Triazole-Based Reversible Targeted Covalent Inhibitor of Cruzipain.

ACS Med Chem Lett

January 2025

Sustainable Chemistry for Metals and Molecules, Department of Chemistry, KU Leuven, Leuven 3000, Belgium.

Cruzipain (CZP) is an essential cysteine protease of , the etiological agent of Chagas disease, and a promising druggable target. To date, no CZP inhibitors have reached clinical use, with research efforts mostly hampered by insufficient potency, limited target selectivity or lack of bioactivity translation from the isolated enzyme to the parasite in cellular environments. In this study, we report the design of , a 1,2,3-triazole-based targeted covalent inhibitor with nanomolar potency (IC = 28 nM) and null inhibition of human cathepsin L.

View Article and Find Full Text PDF

Background: Endemic in more than 20 countries, Chagas disease affects 6.3 million people worldwide, leading to 28,000 new infections and 7700 deaths each year. Previous meta-analyses on antiparasitic treatment need updates to encompass recent studies and to assess key clinically meaningful endpoints.

View Article and Find Full Text PDF

Background: Nurses provide essential care for symptomatic chronic Chagas disease carriers, caused by Trypanosoma cruzi, offering crucial support, symptom management, medication administration, and monitoring to enhance their health-related quality of life.

Objective: To increase healthcare professionals' awareness of the critical role played by high-quality care in the management of patients with chronic Chagas disease.

Methods: This scoping review employed the PRISMA-ScR method as a framework for article selection.

View Article and Find Full Text PDF

Eco-epidemiological Survey of Trypanosoma cruzi in Dogs from Mendoza, Argentina.

Ecohealth

January 2025

Laboratorio de Medicina y Endocrinología de la Fauna Silvestre, IMBECU, UNCuyo - CONICET, Av. Dr. Adrian Ruiz Leal s/n, Parque General San Martín, Mendoza, Argentina.

Urban domestic dog populations can provide important clues about the eco-epidemiological characteristics of Trypanosoma cruzi, the causative agent of Chagas disease (ChD). Given the limited data on ChD from the Metropolitan Area of Mendoza, Argentina, a seroprevalence survey of 327 dogs across an urban-rural gradient was conducted between April 2018 and May 2019. Seropositive cases were analyzed considering host, social, and environmental factors, subtypes (DTUs), and bloodstream parasite load.

View Article and Find Full Text PDF

Background: Determining esophageal and colon involvement in patients with Chagas disease occurs through invasive and uncomfortable examinations, which in most cases are not performed. The objective of this study was to assess the involvement of anti-M2-pyruvate kinase (M2-PK) autoantibodies in the development of digestive alterations and/or in the diagnosis of the digestive form of human Chagas disease.

Methods: The total IgG and isotype (IgG1, IgG2, IgG3, IgG4) production was quantified using the antigen of Trypanosoma cruzi and the human M2-PK recombinant protein via the ELISA technique.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!